Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin

Antiviral Therapy

Volumn 17, Issue 5, 2012, Pages 927-932

  Larrey, Dominique ^a   Carenco, Christophe ^a   Guyader, Dominique ^b   Boyer, Nathalie ^c   Benhamou, Yves ^d   Pageaux, Georges Philippe ^a   Rouzier, Regine ^e   Marcellin, Patrick ^c  

^a HÔPITAL SAINT ELOI   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c BEAUJON HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Phase I/II Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DANOPREVIR; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LIVER TOXICITY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; SUSTAINED VIROLOGICAL RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LACTAMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865790751     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2126     Document Type: Article

References (19)

1. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011; 53:1090-1099.
2. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4a protease recombinant viruses. Gastroenterology 2011; 141:1067-1079.
3. Forestier N, Larrey D, Marcellin P, et al. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon a-2a and ribavirin in patients with chronic hepatitis C. J Infect Dis 2011; 204:601-608.
4. Forestier N, Larrey D, Guyader D, et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a Phase 1b multiple ascending dose study. J Hepatol 2011; 54:1130-1136.
5. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475.
6. FDA. Victrelis prescribing information. (Updated May 2011. Accessed 17 April 2012.) Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2011/202258lbl.pdf
7. FDA. Incivek prescribing information. (Updated May 2011. Accessed 17 April 2012.) Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2011/201917lbl.pdf
8. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
9. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
10. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
11. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
13. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
14. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
15. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
16. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
17. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 2010; 376:705-716.
18. Terrault N, Cooper C, Balart L, et al. High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PEGIFNa2A (40KD) and ribavirin (P/R) in treatment-naive HCV genotype 1 (G1) patients: results from the ATLAS study. Hepatology 2011; 54 Suppl:85A.
19. Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J Hepatol 2011; 55:972-979.